<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062881" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of mycosis fungoides and the Sézary syndrome.</SummaryDescription><SummaryURL xref="http://cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">Mycosis Fungoides and the Sézary Syndrome (PDQ®): Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000038223">mycosis fungoides/Sezary syndrome</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Mycosis Fungoides and the Sézary Syndrome Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Navlabel">Mycosis Fungoides &amp; Sézary Syndrome Treatment</AltTitle><AltTitle TitleType="Short">Mycosis Fungoides and the Sézary Syndrome Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000038223">mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Mycosis Fungoides and the Sézary Syndrome</Title><SummarySection id="_287"><Title>Clinical Presentation</Title><Para id="_3">Mycosis fungoides and the Sézary syndrome (MF/SS) are neoplasias of malignant
T lymphocytes that usually possess the helper/inducer cell surface phenotype. 
These kinds of neoplasms initially present as skin involvement and as such have been
classified as cutaneous T-cell lymphomas.<Reference refidx="1"/>  These types of lymphomas are included in the
Revised European-American Lymphoma  classification as low-grade T-cell
lymphomas, which should be distinguished from other T-cell lymphomas that
involve the skin, such as anaplastic large cell lymphoma (CD30 positive),
peripheral T-cell lymphoma (CD30 negative, with no epidermal involvement),
adult T-cell leukemia/lymphoma (usually with systemic involvement), or
subcutaneous panniculitic T-cell lymphoma.<Reference refidx="2"/><Reference refidx="3"/>  These histologic types
of T-cell lymphomas are discussed in another PDQ summary. (Refer to the PDQ
summary on <SummaryRef href="CDR0000062707" url="/types/lymphoma/hp/adult-nhl-treatment-pdq">Adult Non-Hodgkin Lymphoma Treatment</SummaryRef> for more information.)  In
addition, a number of benign or very indolent conditions can be confused with
mycosis fungoides.  Consultation with a pathologist who has
expertise in distinguishing these conditions is important.<Reference refidx="4"/>
</Para></SummarySection><SummarySection id="_286"><Title>Prognosis and Survival</Title><Para id="_4">The prognosis of patients with MF/SS is based on the extent of disease at
presentation (stage).<Reference refidx="5"/> The presence of lymphadenopathy and involvement of
peripheral blood and viscera increase in likelihood with worsening cutaneous
involvement and define poor prognostic groups.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/>  The median survival
following diagnosis varies according to stage.  Patients with stage IA disease
have a median survival of 20 or more years.  The majority of deaths for this
group are not caused by, nor are they related to, MF.<Reference refidx="8"/>  In contrast, more
than 50% of patients with stage III through stage IV disease die of MF, with a
median survival of less than 5 years.<Reference refidx="7"/><Reference refidx="9"/><Reference refidx="10"/>
A report on 1,798 patients from the <ExternalRef xref="http://seer.cancer.gov/">National Cancer Institute's Surveillance, Epidemiology, and End Results Program</ExternalRef> (SEER) database found an increase in second malignancies (standardized incidence ratio of 1.32; 95% confidence interval, 1.15–1.52), especially for Hodgkin and non-Hodgkin lymphoma and for myeloma.<Reference refidx="11"/></Para><Para id="_5">Typically, the natural history of MF is indolent.<Reference refidx="12"/>  Symptoms of the disease
may present for long periods, an   average of 2 to 10 years, as waxing and waning
cutaneous eruptions prior to biopsy confirmation.  MF/SS is treatable with
available topical and/or systemic therapies.  Curative modalities, however,  have
thus far proven elusive, with the possible exception of patients with minimal
disease confined to the skin.
</Para><Para id="_6">Cutaneous disease typically progresses from an eczematous patch/plaque stage
covering less than 10% of the body surface (T1) to plaque stage covering
10%  or more of the body surface (T2), and finally to tumors
(T3) that frequently undergo necrotic ulceration.<Reference refidx="4"/><Reference refidx="13"/>  A retrospective study  with a median follow-up of 14.5 years showed that 20% of the 1,422 patients progressed from stage I or II disease to stage III or IV disease.<Reference refidx="14"/> SS presents with generalized erythroderma (T4) and peripheral blood involvement.  However, there is some disagreement about  whether the MF and SS are actually variants of the same disease.<Reference refidx="15"/> The same retrospective study with a median follow-up of 14.5 years found that only 3% of 1,422 patients progressed from MF to SS.<Reference refidx="14"/> There is consensus that patients with SS have a poor prognosis (median survival of 4 years).<Reference refidx="16"/> Cytologic transformation from a low-grade lymphoma to a high-grade
lymphoma (large-cell transformation) occurs rarely (&lt;5%) during the course of these diseases and is associated
with a poor prognosis.<Reference refidx="17"/><Reference refidx="18"/>  A retrospective analysis of 100 cases with large-cell transformation found reduced disease-specific survival with extracutaneous transformation, increased extent of skin lesions, and CD30 negativity.<Reference refidx="19"/> A common cause of death during the tumor phase is
sepsis from <ScientificName>Pseudomonas aeruginosa</ScientificName> or <ScientificName>Staphylococcus aureus</ScientificName> caused by  chronic skin
infection with staph species and subsequent systemic infections.<Reference refidx="13"/>
</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="15128898">Girardi M, Heald PW, Wilson LD: The pathogenesis of mycosis fungoides. N Engl J Med 350 (19): 1978-88, 2004.</Citation><Citation idx="2" PMID="9207472" MedlineID="97351096">Willemze R, Kerl H, Sterry W, et al.: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90 (1): 354-71, 1997.</Citation><Citation idx="3" PMID="8068936" MedlineID="94348057">Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (5): 1361-92, 1994.</Citation><Citation idx="4" PMID="10920140" MedlineID="20381203">Siegel RS, Pandolfino T, Guitart J, et al.: Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 18 (15): 2908-25, 2000.</Citation><Citation idx="5" PMID="20855822">Agar NS, Wedgeworth E, Crichton S, et al.: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 (31): 4730-9, 2010.</Citation><Citation idx="6" PMID="22850569">Talpur R, Singh L, Daulat S, et al.: Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 18 (18): 5051-60, 2012.</Citation><Citation idx="7" PMID="12873880">Kim YH, Liu HL, Mraz-Gernhard S, et al.: Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 139 (7): 857-66, 2003.</Citation><Citation idx="8" PMID="8915308" MedlineID="97072542">Kim YH, Jensen RA, Watanabe GL, et al.: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132 (11): 1309-13, 1996.</Citation><Citation idx="9" PMID="10071312" MedlineID="99168870">Zackheim HS, Amin S, Kashani-Sabet M, et al.: Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 40 (3): 418-25, 1999.</Citation><Citation idx="10" PMID="11157031" MedlineID="21104129">de Coninck  EC, Kim YH, Varghese A, et al.: Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. J Clin Oncol 19 (3): 779-84, 2001.</Citation><Citation idx="11" PMID="17224541">Huang KP, Weinstock MA, Clarke CA, et al.: Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts. Arch Dermatol 143 (1): 45-50, 2007.</Citation><Citation idx="12" PMID="8839829" MedlineID="96437013">Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sezary syndrome. Blood 88 (7): 2385-409, 1996.</Citation><Citation idx="13" PMID="8622396" MedlineID="96177218">Lorincz AL: Cutaneous T-cell lymphoma (mycosis fungoides) Lancet 347 (9005): 871-6, 1996.</Citation><Citation idx="14" PMID="22674564">Quaglino P, Pimpinelli N, Berti E, et al.: Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer 118 (23): 5830-9, 2012.</Citation><Citation idx="15" PMID="21145619">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011.</Citation><Citation idx="16" PMID="22640839">Kubica AW, Davis MD, Weaver AL, et al.: Sézary syndrome: a study of 176 patients at Mayo Clinic. J Am Acad Dermatol 67 (6): 1189-99, 2012.</Citation><Citation idx="17" PMID="7661601" MedlineID="95390698">Kim YH, Bishop K, Varghese A, et al.: Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 131 (9): 1003-8, 1995.</Citation><Citation idx="18" PMID="18647960">Arulogun SO, Prince HM, Ng J, et al.: Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood 112 (8): 3082-7, 2008.</Citation><Citation idx="19" PMID="22160616">Benner MF, Jansen PM, Vermeer MH, et al.: Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood 119 (7): 1643-9, 2012.</Citation></ReferenceSection></SummarySection><SummarySection id="_7"><SectMetaData><SpecificDiagnosis ref="CDR0000038223">mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Mycosis Fungoides and the Sézary Syndrome</Title><Para id="_8">The histologic diagnosis of mycosis fungoides and the Sézary syndrome (MF/SS)
is usually difficult to determine in the initial stages of the disease and may require the
review of multiple biopsies by an experienced pathologist.
</Para><Para id="_9">A definitive diagnosis from a skin biopsy requires the presence of MF/SS cells
(convoluted lymphocytes), a band-like upper dermal infiltrate, and epidermal
infiltrations with Pautrier abscesses (collections of neoplastic
lymphocytes).  A definitive diagnosis of SS may be made from a peripheral blood
evaluation when skin biopsies are consistent with the diagnosis. Supportive evidence for circulating Sézary cells is provided by T-cell receptor gene analysis, identification of the atypical lymphocytes with hyper-convoluted or cerebriform nuclei, and flow cytometry with the characteristic deletion of cell surface markers such as CD7 and CD26.   However, none of these is individually pathognomonic for lymphoma.  <Reference refidx="1"/><Reference refidx="2"/></Para><ReferenceSection><Citation idx="1" PMID="21145619">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011.</Citation><Citation idx="2" PMID="11745245" MedlineID="21610187">Fraser-Andrews EA, Russell-Jones R, Woolford AJ, et al.: Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sézary syndrome. Cancer 92 (7): 1745-52, 2001.</Citation></ReferenceSection></SummarySection><SummarySection id="_10"><SectMetaData><SpecificDiagnosis ref="CDR0000038223">mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Mycosis Fungoides and the Sézary Syndrome</Title><Para id="_11">The stages that follow are defined by TNM classification.  Peripheral blood
involvement with mycosis fungoides or Sézary syndrome (MF/SS) cells is correlated with more
advanced skin stage, lymph node and visceral involvement, and shortened
survival. </Para><Para id="_214">MF/SS have a formal staging system proposed by the International Society for Cutaneous Lymphomas (ISCL) and the European Organization of Research and Treatment of Cancer (EORTC).<Reference refidx="1"/><Reference refidx="2"/></Para><SummarySection id="_215"><Title>Definitions of TNM</Title><Para id="_231">The American Joint Committee on Cancer (AJCC) has designated staging by TNM classification to define MF.<Reference refidx="3"/></Para><Table id="_216"><Title>Table 1.  ISCL/EORTC Revision to the Classification of Mycosis Fungoides and the Sézary Syndrome<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="19.76%"/><ColSpec ColName="col2" ColNum="2" ColWidth="80.23%"/><THead><Row><entry Align="Center" NameEnd="col2" NameSt="col1"><Emphasis>Skin</Emphasis></entry></Row></THead><TFoot><Row><entry NameEnd="col2" NameSt="col1">EORTC = European Organization of Research and Treatment of Cancer; ISCL = International Society for Cutaneous Lymphomas; NCI = National Cancer Institute.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Primary cutaneous lymphomas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, p 613-5.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>For skin, patch indicates any size skin lesion without significant elevation or induration. Presence/absence of hypo- or hyperpigmentation, scale, crusting, and/or poikiloderma should be noted.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>c</Superscript>For skin, plaque indicates any size skin lesion that is elevated or indurated. Presence or absence of scale, crusting, and/or poikiloderma should be noted. Histologic features such as folliculotropism or large-cell transformation (&gt;25% large cells), CD30+ or CD30-, and clinical features, such as ulceration, are important to document.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>d</Superscript>For skin, tumor indicates at least 1 cm diameter solid or nodular lesion with evidence of depth and/or vertical growth. Note total number of lesions, total volume of lesions, largest size lesion, and region of body involved. Also, note if histologic evidence of large cell transformation has occurred. Phenotyping for CD30 is encouraged.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>e</Superscript>For node, abnormal peripheral lymph node(s) indicates any palpable peripheral node that on physical examination is firm, irregular, clustered, fixed, or ≥1.5 cm in diameter. Node groups examined on physical examination include: cervical, supraclavicular, epitrochlear, axillary, and inguinal. Central nodes, which are not generally amenable to pathologic assessment, are not currently considered in the nodal classification unless used to establish N3 histopathologically.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>f</Superscript>A T-cell clone is defined by polymerase chain reaction  or Southern blot analysis of the T-cell receptor (TCR) gene.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>g</Superscript>For viscera, spleen and liver may be diagnosed by imaging criteria.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>h</Superscript>For blood, Sézary cells are defined as lymphocytes with hyper-convoluted cerebriform nuclei. If Sézary cells are not able to be used to determine tumor burden for B2, then one of the following modified ISCL criteria along with a positive clonal rearrangement of the TCR may be used instead: (1) expanded CD4+ or CD3+ cells with CD4/CD8 ratio of ≥10; and (2) expanded CD4+ cells with abnormal immunophenotype, including loss of CD7 or CD26.</entry></Row></TFoot><TBody><Row><entry>T1</entry><entry>Limited patches,<Superscript>b</Superscript> papules, and/or plaques<Superscript>c</Superscript> covering  &lt;10% of the skin surface. May further stratify into T1a (patch only) vs. T1b (plaque ± patch).</entry></Row><Row><entry>T2</entry><entry>Patches, papules, or plaques covering ≥10% of the skin surface. May further stratify into T2a (patch only) vs. T2b (plaque ± patch).</entry></Row><Row><entry>T3</entry><entry>≥1 tumor<Superscript>d</Superscript> (≥1 cm diameter).</entry></Row><Row><entry>T4</entry><entry>Confluence of erythema covering ≥80% of body surface  area.</entry></Row><Row><entry Align="Center" NameEnd="col2" NameSt="col1"><Strong><Emphasis>Node</Emphasis></Strong></entry></Row><Row><entry>N0</entry><entry>No clinically abnormal peripheral lymph nodes;<Superscript>e</Superscript> biopsy not required.</entry></Row><Row><entry>N1</entry><entry>Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 1 or NCI LN0–2.</entry></Row><Row><entry>N1a</entry><entry>Clone negative.<Superscript>f</Superscript></entry></Row><Row><entry>N1b</entry><entry>Clone positive.<Superscript>f</Superscript></entry></Row><Row><entry>N2</entry><entry>Clinically abnormal peripheral lymph nodes; histopathology Dutch grade 2 or NCI LN3.</entry></Row><Row><entry>N2a</entry><entry>Clone negative.<Superscript>f</Superscript></entry></Row><Row><entry>N2b</entry><entry>Clone positive.<Superscript>f</Superscript></entry></Row><Row><entry>N3</entry><entry>Clinically abnormal peripheral lymph nodes; histopathology Dutch grades 3–4 or NCI LN4; clone positive or negative.</entry></Row><Row><entry>Nx</entry><entry>Clinically abnormal peripheral lymph nodes; no histologic confirmation.</entry></Row><Row><entry Align="Center" NameEnd="col2" NameSt="col1"><Strong><Emphasis>Visceral</Emphasis></Strong></entry></Row><Row><entry>M0</entry><entry>No visceral organ involvement.</entry></Row><Row><entry>M1</entry><entry>Visceral involvement (must have pathology confirmation,<Superscript>g</Superscript> and organ involved should be specified).</entry></Row><Row><entry Align="Center" NameEnd="col2" NameSt="col1"><Strong><Emphasis>Peripheral Blood Involvement</Emphasis></Strong></entry></Row><Row><entry>B0</entry><entry>Absence of significant blood involvement: ≤5% of peripheral blood lymphocytes are atypical (Sézary) cells.<Superscript>h</Superscript></entry></Row><Row><entry>B0a</entry><entry>Clone negative.<Superscript>f</Superscript></entry></Row><Row><entry>B0b</entry><entry>Clone positive.<Superscript>f</Superscript></entry></Row><Row><entry>B1</entry><entry>Low blood-tumor burden: &gt;5% of peripheral blood lymphocytes are atypical (Sézary) cells but does not meet the criteria of B2.</entry></Row><Row><entry>B1a</entry><entry>Clone negative.<Superscript>f</Superscript></entry></Row><Row><entry>B1b</entry><entry>Clone positive.<Superscript>f</Superscript></entry></Row><Row><entry>B2</entry><entry>High blood-tumor burden: ≥1,000/μL Sézary cells<Superscript>h</Superscript> with positive clone.<Superscript>f</Superscript></entry></Row></TBody></TGroup></Table><Table id="_217"><Title>Table 2.  Anatomic Stage/Prognostic Groups<Superscript>a,</Superscript><Superscript>b</Superscript></Title><TGroup Cols="5"><ColSpec ColName="col1" ColNum="1" ColWidth="20.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="20.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="20.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="20.00%"/><ColSpec ColName="col5" ColNum="5" ColWidth="20.00%"/><THead><Row><entry Align="Center" NameEnd="col5" NameSt="col1">ISCL/EORTC Revision to the Staging of Mycosis Fungoides and the Sézary Syndrome</entry></Row><Row><entry Align="Center">Stage</entry><entry Align="Center">T</entry><entry Align="Center">N</entry><entry Align="Center">M</entry><entry Align="Center">Peripheral Blood Involvement</entry></Row></THead><TFoot><Row><entry NameEnd="col5" NameSt="col1">EORTC = European Organization of Research and Treatment of Cancer; ISCL = International Society for Cutaneous Lymphomas.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Primary cutaneous lymphomas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, p 613-5.</entry></Row><Row><entry NameEnd="col5" NameSt="col1"><Superscript>b</Superscript>Adapted from Olsen et al.<Reference refidx="1"/></entry></Row></TFoot><TBody><Row><entry>IA</entry><entry>1</entry><entry>0</entry><entry>0</entry><entry>0, 1</entry></Row><Row><entry>IB</entry><entry>2</entry><entry>0</entry><entry>0</entry><entry>0, 1</entry></Row><Row><entry> IIA</entry><entry>1, 2</entry><entry>1, 2</entry><entry>0</entry><entry>0, 1</entry></Row><Row><entry>IIB</entry><entry>3</entry><entry>0–2</entry><entry>0</entry><entry>0, 1</entry></Row><Row><entry> III</entry><entry>4</entry><entry>0–2</entry><entry>0</entry><entry>0, 1</entry></Row><Row><entry>IIIA</entry><entry>4</entry><entry>0–2</entry><entry>0</entry><entry>0</entry></Row><Row><entry> IIIB</entry><entry>4</entry><entry>0–2</entry><entry>0</entry><entry>1</entry></Row><Row><entry> IVA1</entry><entry>1–4</entry><entry>0–2</entry><entry>0</entry><entry>2</entry></Row><Row><entry>IVA2</entry><entry>1–4</entry><entry>3</entry><entry>0</entry><entry>0–2</entry></Row><Row><entry>IVB</entry><entry>1–4</entry><entry>0–3</entry><entry>1</entry><entry>0–2</entry></Row></TBody></TGroup></Table></SummarySection><ReferenceSection><Citation idx="1" PMID="17540844">Olsen E, Vonderheid E, Pimpinelli N, et al.: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 110 (6): 1713-22, 2007.</Citation><Citation idx="2" PMID="20855822">Agar NS, Wedgeworth E, Crichton S, et al.: Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 28 (31): 4730-9, 2010.</Citation><Citation idx="3">Primary cutaneous lymphomas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 614-5.</Citation></ReferenceSection></SummarySection><SummarySection id="_50"><SectMetaData><SpecificDiagnosis ref="CDR0000038223">mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview</Title><Para id="_51">Treatment options for patients with mycosis fungoides and the Sézary syndrome (MF/SS) include:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/> </Para><ItemizedList id="_131" Style="bullet"><ListItem>Topical corticosteroids.</ListItem><ListItem>Topical
chemotherapy with mechlorethamine (nitrogen mustard) or carmustine (BCNU).
</ListItem><ListItem>Psoralen and ultraviolet A radiation (PUVA). </ListItem><ListItem>Ultraviolet B radiation (UVB).</ListItem><ListItem>Total-skin electron-beam
radiation (TSEB). </ListItem><ListItem>Radiation of symptomatic skin lesions. </ListItem><ListItem>Interferon-alpha
or interferon-gamma alone or in combination with topical therapy.</ListItem><ListItem>Single-agent and multiagent
chemotherapy.</ListItem><ListItem>Bexarotene (topical gel or oral); retinoids.</ListItem><ListItem>Denileukin diftitox (recombinant fusion protein of diphtheria toxin fragments and interleukin-2 sequences).</ListItem><ListItem>Vorinostat or romidepsin or other histone deacetylase inhibitors.</ListItem><ListItem>Pralatrexate (folate analog).<Reference refidx="4"/></ListItem><ListItem>Alemtuzumab (a humanized monoclonal antibody targeting the CD52 antigen).</ListItem><ListItem>Combined modality treatment.</ListItem></ItemizedList><Para id="_132">These types of treatments produce
remissions, but long-term remissions are uncommon.  Treatment, therefore,  is considered palliative for most patients,
though major symptomatic improvement is regularly achieved.  Survival in excess of 8 years, however,  is common for patients with early stages of disease.  All patients with MF/SS are
candidates for clinical trials evaluating new approaches to treatment.
</Para><Para id="_52">Current areas of interest in clinical trials for MF confined to the skin
include combined modality therapies containing both topical and systemic agents
such as TSEB combined with chemotherapy, topical mechlorethamine or PUVA
combined with interferon, or wide-field radiation techniques with PUVA. 
Reports are available of activity for extracorporeal photochemotherapy using
psoralen; interferon-gamma or interferon-alpha; pentostatin; retinoids; fludarabine;
acyclovir; 2-chlorodeoxyadenosine; serotherapy with unlabeled,
toxin-labeled, or radiolabeled monoclonal antibodies; cell surface receptor
ligand-toxin fusion protein; and, methotrexate.<Reference refidx="3"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/>
 Antigen-specific vaccination using dendritic cells <Reference refidx="15"/> and UVB  are also under clinical evaluation.</Para><ReferenceSection><Citation idx="1" PMID="19696197">Prince HM, Whittaker S, Hoppe RT: How I treat mycosis fungoides and Sézary syndrome. Blood 114 (20): 4337-53, 2009.</Citation><Citation idx="2" PMID="16574401">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.</Citation><Citation idx="3" PMID="21145619">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011.</Citation><Citation idx="4" PMID="22394596">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012.</Citation><Citation idx="5" PMID="2104937" MedlineID="90112480">Kaplan EH, Rosen ST, Norris DB, et al.: Phase II study of recombinant human interferon gamma for treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82 (3): 208-12, 1990.</Citation><Citation idx="6" PMID="1401279" MedlineID="93017138">Heald P, Rook A, Perez M, et al.: Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 27 (3): 427-33, 1992.</Citation><Citation idx="7" PMID="3549989" MedlineID="87168565">Rosen ST, Zimmer AM, Goldman-Leikin R, et al.: Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 5 (4): 562-73, 1987.</Citation><Citation idx="8" PMID="1453206" MedlineID="93085392">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992.</Citation><Citation idx="9" PMID="1353380" MedlineID="92345592">Saven A, Carrera CJ, Carson DA, et al.: 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80 (3): 587-92, 1992.</Citation><Citation idx="10" PMID="7799028" MedlineID="95096954">Kuzel TM, Roenigk HH Jr, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.</Citation><Citation idx="11" PMID="11208829" MedlineID="21126170">Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2): 376-88, 2001.</Citation><Citation idx="12" PMID="10920140" MedlineID="20381203">Siegel RS, Pandolfino T, Guitart J, et al.: Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 18 (15): 2908-25, 2000.</Citation><Citation idx="13" PMID="11331325" MedlineID="21229775">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.</Citation><Citation idx="14" PMID="14576667">Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003.</Citation><Citation idx="15" PMID="12714511">Maier T, Tun-Kyi A, Tassis A, et al.: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102 (7): 2338-44, 2003.</Citation></ReferenceSection></SummarySection><SummarySection id="_54"><SectMetaData><SpecificDiagnosis ref="CDR0000038224">stage I mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage I Mycosis Fungoides</Title><Para id="_55">Since several forms of treatment can produce complete resolution of skin
lesions in this stage, the choice of therapy is dependent on local expertise
and the facilities available.  With therapy, the survival of patients with
stage IA disease can be expected to be the same as age and gender-matched
controls.<Reference refidx="1"/><Reference refidx="2"/>
</Para><Para id="_56"><Strong>Treatment options:</Strong><Reference refidx="3"/>
</Para><OrderedList id="_106" Style="Arabic" Compact="No"><ListItem>Psoralen and ultraviolet A radiation (PUVA).  Therapeutic trials with PUVA
have shown a 62% to 90% complete remission rate with early cutaneous stages
achieving the best responses.  Continued maintenance therapy with PUVA at more
protracted intervals is generally required to prolong remission duration.<Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/> 
PUVA combined with interferon alpha-2a is associated with a high response 
rate.<Reference refidx="7"/></ListItem><ListItem>Total-skin electron-beam radiation.  Electron radiation of
appropriate energies will penetrate only to the dermis, and thus the skin alone
can be treated without systemic effects.  This therapy requires considerable
technical expertise to deliver, can result in short- and long-term cutaneous
toxic effects, and is not widely available.  Based on the long-term survival of
these early stage patients, electron-beam radiation therapy is sometimes used with 
curative intent.<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/>  Long-term disease-free survival can be achieved in
patients with unilesional mycosis fungoides treated with local radiation
therapy.<Reference refidx="12"/>
</ListItem><ListItem>Ultraviolet B radiation is under clinical evaluation.</ListItem><ListItem>Symptomatic management with topical corticosteroids.</ListItem><ListItem>Topical mechlorethamine (nitrogen mustard).  Topical application of
mechlorethamine has produced regression of cutaneous lesions, with particular
efficacy in early stages of disease.  The overall complete remission rate is
related to skin stage; 50% to 80% of TNM classification T1, and 25% to 75% of
T2 patients have complete responses.  Treatments are usually continued for 2 to
3 years.  Continuous 5-year disease-free survival may be possible in  as many as 33% of T1 patients.<Reference refidx="8"/><Reference refidx="13"/><Reference refidx="14"/>
</ListItem><ListItem>Local electron-beam radiation or orthovoltage radiation therapy may be
used to palliate areas of bulky or symptomatic skin disease.<Reference refidx="15"/>
</ListItem><ListItem> Interferon-alpha alone or in combination with topical therapy, as evidenced in the ECOG-1495 trial.</ListItem><ListItem>Bexarotene, an oral or topical retinoid (<ProtocolRef href="CDR0000454838" nct_id="NCT00255801">NCT00255801</ProtocolRef>).<Reference refidx="16"/><Reference refidx="17"/></ListItem><ListItem>Oral methotrexate (<ProtocolRef href="CDR0000533393" nct_id="NCT00425555">NCT00425555</ProtocolRef>).<Reference refidx="18"/></ListItem><ListItem>Pegylated liposomal doxorubicin.<Reference refidx="19"/></ListItem><ListItem>Vorinostat or romidepsin or other histone deacetylase inhibitors.<Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/></ListItem><ListItem>Pralatrexate (folate analog).<Reference refidx="23"/></ListItem><ListItem>Denileukin diftitox  (interleukin-2 fused with diphtheria toxin).<Reference refidx="24"/><Reference refidx="25"/></ListItem></OrderedList><SummarySection id="_TrialSearch_54_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_54_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38224&amp;tt=1&amp;format=2&amp;cn=1">stage I mycosis fungoides/Sezary syndrome</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_54_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="8915308" MedlineID="97072542">Kim YH, Jensen RA, Watanabe GL, et al.: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 132 (11): 1309-13, 1996.</Citation><Citation idx="2" PMID="10071312" MedlineID="99168870">Zackheim HS, Amin S, Kashani-Sabet M, et al.: Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 40 (3): 418-25, 1999.</Citation><Citation idx="3" PMID="16574401">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.</Citation><Citation idx="4" PMID="7622650" MedlineID="95348292">Herrmann JJ, Roenigk HH Jr, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995.</Citation><Citation idx="5" PMID="1626959" MedlineID="92328537">Ramsay DL, Lish KM, Yalowitz CB, et al.: Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch Dermatol 128 (7): 931-3, 1992.</Citation><Citation idx="6" PMID="15781671">Querfeld C, Rosen ST, Kuzel TM, et al.: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 (3): 305-11, 2005.</Citation><Citation idx="7" PMID="7799028" MedlineID="95096954">Kuzel TM, Roenigk HH Jr, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.</Citation><Citation idx="8" PMID="10192339" MedlineID="99206557">Chinn DM, Chow S, Kim YH, et al.: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43 (5): 951-8, 1999.</Citation><Citation idx="9" PMID="9276369" MedlineID="97420384">Quirós PA, Jones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38 (5): 1027-35, 1997.</Citation><Citation idx="10" PMID="15001254">Ysebaert L, Truc G, Dalac S, et al.: Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58 (4): 1128-34, 2004.</Citation><Citation idx="11" PMID="21576575">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011.</Citation><Citation idx="12" PMID="9788416" MedlineID="99002465">Micaily B, Miyamoto C, Kantor G, et al.: Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys 42 (2): 361-4, 1998.</Citation><Citation idx="13" PMID="23069814">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013.</Citation><Citation idx="14" PMID="16172308">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005.</Citation><Citation idx="15" PMID="22818412">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013.</Citation><Citation idx="16" PMID="11331325" MedlineID="21229775">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.</Citation><Citation idx="17" PMID="14576658">Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 49 (5): 801-15, 2003.</Citation><Citation idx="18" PMID="14576667">Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003.</Citation><Citation idx="19" PMID="12942567">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003.</Citation><Citation idx="20" PMID="22981498">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013.</Citation><Citation idx="21" PMID="17577020">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007.</Citation><Citation idx="22" PMID="19826128">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009.</Citation><Citation idx="23" PMID="22394596">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012.</Citation><Citation idx="24" PMID="22738414">Prince HM, Martin AG, Olsen EA, et al.: Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. Leuk Lymphoma 54 (1): 69-75, 2013.</Citation><Citation idx="25" PMID="20212249">Prince HM, Duvic M, Martin A, et al.: Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28 (11): 1870-7, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_63"><SectMetaData><SpecificDiagnosis ref="CDR0000038225">stage II mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage II Mycosis Fungoides</Title><Para id="_64">No curative therapy exists for patients with stage II disease.  The
choice of initial palliative therapy is, therefore,  dependent on the patient’s symptoms and
the local expertise with each modality.  
</Para><Para id="_65">A randomized study  of 103 patients compared combined total-skin electron-beam radiation
(TSEB) plus combination chemotherapy with  conservation therapy consisting of
sequential topical therapies.<Reference refidx="1"/>  In the latter group, combination
chemotherapy was reserved for symptomatic extracutaneous disease or for disease
refractory to topical therapies.  Patients with any stage were eligible. 
Although the complete response rate was higher with combined therapy, toxic
effects were considerably greater,  and no difference was seen in disease-free
or overall survival between the two  groups.<Reference refidx="1"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]

</Para><Para id="_66"><Strong>Treatment options:</Strong><Reference refidx="2"/>
</Para><OrderedList id="_107" Style="Arabic" Compact="No"><ListItem>Psoralen and ultraviolet A radiation (PUVA).  Therapeutic trials with PUVA
have shown a 62% to 90% complete remission rate with early cutaneous stages
achieving the best responses.  Maintenance therapy with PUVA is generally
required to prolong remission duration.<Reference refidx="3"/><Reference refidx="4"/>  PUVA combined with interferon alpha-2a is associated with a high response rate.<Reference refidx="5"/></ListItem><ListItem>TSEB.  Electron radiation of
appropriate energies will penetrate only to the dermis, and the skin
alone can be treated without systemic effects.  This therapy requires a
radiation therapy facility with physics support, considerable technical
expertise, and precise dosimetry.   The therapy can provide excellent palliation with
complete response rates of as much as  80%.<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/>
</ListItem><ListItem>Ultraviolet B radiation is under clinical evaluation.</ListItem><ListItem>Symptomatic management with topical corticosteroids.</ListItem><ListItem>Topical mechlorethamine (nitrogen mustard).  Topical application of
mechlorethamine has produced regression of cutaneous lesions with particular
efficacy in early stages of the disease.  The overall complete remission rate is
related to skin stage; 25% to 75% of TNM classification T2, and as many as  50% of T3
patients have complete responses.  Treatments are usually continued for 2 to 3
years.<Reference refidx="6"/><Reference refidx="10"/><Reference refidx="11"/>
</ListItem><ListItem>Local electron-beam radiation or orthovoltage radiation therapy may also
be used to palliate areas of bulky or symptomatic disease.<Reference refidx="12"/>
</ListItem><ListItem> Interferon-alpha alone or in combination with topical therapy, as evidenced in the ECOG-1495 trial.<Reference refidx="13"/>
</ListItem><ListItem>Bexarotene, an oral or topical retinoid.<Reference refidx="14"/><Reference refidx="15"/>
</ListItem><ListItem>Oral methotrexate (<ProtocolRef href="CDR0000533393" nct_id="NCT00425555">NCT00425555</ProtocolRef>).<Reference refidx="16"/></ListItem><ListItem>Pegylated liposomal doxorubicin.<Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/></ListItem><ListItem>Vorinostat or romidepsin or other histone deacetylase inhibitors.<Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/></ListItem><ListItem>Pralatrexate (folate analog).<Reference refidx="23"/></ListItem><ListItem>Denileukin diftitox  (interleukin-2 fused with diphtheria toxin).<Reference refidx="24"/><Reference refidx="25"/></ListItem></OrderedList><SummarySection id="_TrialSearch_63_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_63_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38225&amp;tt=1&amp;format=2&amp;cn=1">stage II mycosis fungoides/Sezary syndrome</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_63_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="2594037" MedlineID="90081777">Kaye FJ, Bunn PA Jr, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (26): 1784-90, 1989.</Citation><Citation idx="2" PMID="16574401">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.</Citation><Citation idx="3" PMID="7622650" MedlineID="95348292">Herrmann JJ, Roenigk HH Jr, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995.</Citation><Citation idx="4" PMID="15781671">Querfeld C, Rosen ST, Kuzel TM, et al.: Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141 (3): 305-11, 2005.</Citation><Citation idx="5" PMID="7799028" MedlineID="95096954">Kuzel TM, Roenigk HH Jr, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.</Citation><Citation idx="6" PMID="10192339" MedlineID="99206557">Chinn DM, Chow S, Kim YH, et al.: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 43 (5): 951-8, 1999.</Citation><Citation idx="7" PMID="9276369" MedlineID="97420384">Quirós PA, Jones GW, Kacinski BM, et al.: Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys 38 (5): 1027-35, 1997.</Citation><Citation idx="8" PMID="15001254">Ysebaert L, Truc G, Dalac S, et al.: Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation). Int J Radiat Oncol Biol Phys 58 (4): 1128-34, 2004.</Citation><Citation idx="9" PMID="21576575">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011.</Citation><Citation idx="10" PMID="23069814">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013.</Citation><Citation idx="11" PMID="16172308">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005.</Citation><Citation idx="12" PMID="22818412">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013.</Citation><Citation idx="13" PMID="1453206" MedlineID="93085392">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992.</Citation><Citation idx="14" PMID="11331325" MedlineID="21229775">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.</Citation><Citation idx="15" PMID="14576658">Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 49 (5): 801-15, 2003.</Citation><Citation idx="16" PMID="14576667">Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003.</Citation><Citation idx="17" PMID="23045580">Dummer R, Quaglino P, Becker JC, et al.: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30 (33): 4091-7, 2012.</Citation><Citation idx="18" PMID="12942567">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003.</Citation><Citation idx="19" PMID="18559761">Quereux G, Marques S, Nguyen JM, et al.: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144 (6): 727-33, 2008.</Citation><Citation idx="20" PMID="22981498">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013.</Citation><Citation idx="21" PMID="17577020">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007.</Citation><Citation idx="22" PMID="19826128">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009.</Citation><Citation idx="23" PMID="22394596">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012.</Citation><Citation idx="24" PMID="22738414">Prince HM, Martin AG, Olsen EA, et al.: Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. Leuk Lymphoma 54 (1): 69-75, 2013.</Citation><Citation idx="25" PMID="20212249">Prince HM, Duvic M, Martin A, et al.: Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28 (11): 1870-7, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_73"><SectMetaData><SpecificDiagnosis ref="CDR0000038226">stage III mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage III Mycosis Fungoides</Title><Para id="_75">No curative treatment exists for patients with stage III disease.  The initial choice of palliative therapy is, therefore,  dependent on the local expertise
with each modality.</Para><Para id="_76">A randomized study of 103 patients compared combined total-skin electron-beam radiation
(TSEB) plus combination chemotherapy with conservation therapy consisting of
sequential topical therapies.<Reference refidx="1"/>  In the latter group, combination
chemotherapy was reserved for symptomatic extracutaneous disease or for disease
refractory to topical therapies.  Patients with any stage were eligible. 
Although the complete response rate was higher with combined therapy, toxic
effects were considerably greater, and no difference was seen in disease-free
or overall survival between the two groups.<Reference refidx="1"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]
</Para><Para id="_77"><Strong>Treatment options</Strong> (note that in this clinical setting, the skin is
easily injured; any of the topical therapies must be administered with extreme
caution)<Strong>:</Strong><Reference refidx="2"/><Reference refidx="3"/>
</Para><OrderedList id="_108" Style="Arabic" Compact="No"><ListItem> Psoralen and ultraviolet A radiation (PUVA).  Therapeutic trials with PUVA
have shown a 62% to 90% complete remission rate with early cutaneous stages
achieving the best responses.  PUVA may be used in conjunction with systemic
treatment.  Maintenance therapy  with PUVA is generally required to prolong
remission duration.<Reference refidx="4"/>  PUVA combined with interferon alpha-2a is associated
with a high response rate.<Reference refidx="5"/></ListItem><ListItem>TSEB.  Electron radiation of
appropriate energies will penetrate only to the dermis, and thus the skin alone
can be treated without systemic effects.  This therapy requires an excellent
radiation therapy facility with physics support, considerable technical
expertise, and precise dosimetry.  The therapy can produce excellent
palliation with complete response rates of as much as  80%.<Reference refidx="6"/><Reference refidx="7"/>
</ListItem><ListItem>Ultraviolet B radiation is under clinical evaluation.</ListItem><ListItem>Symptomatic management with topical corticosteroids.</ListItem><ListItem>Local electron-beam radiation or orthovoltage radiation therapy may also
be used to palliate areas of bulky or symptomatic disease.<Reference refidx="8"/>
</ListItem><ListItem> Fludarabine, 2-chlorodeoxyadenosine, and pentostatin are active agents for
mycosis fungoides  and SS.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>
</ListItem><ListItem>Interferon-alpha alone or in combination with topical therapy, as evidenced in ECOG-1495.<Reference refidx="10"/><Reference refidx="13"/></ListItem><ListItem>Denileukin diftitox (interleukin-2 fused with diphtheria toxin).<Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/></ListItem><ListItem>Systemic chemotherapy (single agent or combination) often combined with
treatment directed at the skin.<Reference refidx="1"/><Reference refidx="17"/><Reference refidx="18"/>
</ListItem><ListItem> Extracorporeal photochemotherapy.<Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/>
</ListItem><ListItem>Topical mechlorethamine (nitrogen mustard).  This form of treatment may be
used palliatively or to supplement therapeutic approaches directed against
nodal or visceral disease.  The overall complete remission rate of TNM
classification T4 patients is 20% to 40%.  Treatments are usually continued for
2 to 3 years.<Reference refidx="22"/><Reference refidx="23"/>
</ListItem><ListItem>Bexarotene, an oral or topical retinoid.<Reference refidx="24"/><Reference refidx="25"/></ListItem><ListItem>Oral methotrexate (<ProtocolRef href="CDR0000533393" nct_id="NCT00425555">NCT00425555</ProtocolRef>).<Reference refidx="26"/></ListItem><ListItem>Pegylated liposomal doxorubicin.<Reference refidx="27"/><Reference refidx="28"/><Reference refidx="29"/></ListItem><ListItem>Vorinostat or romidepsin or other histone deacetylase inhibitors.<Reference refidx="3"/><Reference refidx="30"/><Reference refidx="31"/><Reference refidx="32"/></ListItem><ListItem>Pralatrexate (folate analog).<Reference refidx="33"/></ListItem><ListItem>Alemtuzumab (a humanized monoclonal antibody targeting the CD52 antigen).<Reference refidx="3"/></ListItem></OrderedList><SummarySection id="_TrialSearch_73_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_73_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38226&amp;tt=1&amp;format=2&amp;cn=1">stage III mycosis fungoides/Sezary syndrome</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_73_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="2594037" MedlineID="90081777">Kaye FJ, Bunn PA Jr, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (26): 1784-90, 1989.</Citation><Citation idx="2" PMID="16574401">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.</Citation><Citation idx="3" PMID="21145619">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011.</Citation><Citation idx="4" PMID="7622650" MedlineID="95348292">Herrmann JJ, Roenigk HH Jr, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995.</Citation><Citation idx="5" PMID="7799028" MedlineID="95096954">Kuzel TM, Roenigk HH Jr, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.</Citation><Citation idx="6" PMID="10223240" MedlineID="99237751">Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 85 (9): 1985-95, 1999.</Citation><Citation idx="7" PMID="21576575">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011.</Citation><Citation idx="8" PMID="22818412">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013.</Citation><Citation idx="9" PMID="1353380" MedlineID="92345592">Saven A, Carrera CJ, Carson DA, et al.: 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80 (3): 587-92, 1992.</Citation><Citation idx="10" PMID="1453206" MedlineID="93085392">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992.</Citation><Citation idx="11" PMID="7931473" MedlineID="95016867">Foss FM, Ihde DC, Linnoila IR, et al.: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 12 (10): 2051-9, 1994.</Citation><Citation idx="12" PMID="10506607" MedlineID="99438177">Kurzrock R, Pilat S, Duvic M: Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 17 (10): 3117-21, 1999.</Citation><Citation idx="13" PMID="8522486" MedlineID="96087568">Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 (5): 1089-107, 1995.</Citation><Citation idx="14" PMID="22738414">Prince HM, Martin AG, Olsen EA, et al.: Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. Leuk Lymphoma 54 (1): 69-75, 2013.</Citation><Citation idx="15" PMID="11208829" MedlineID="21126170">Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2): 376-88, 2001.</Citation><Citation idx="16" PMID="20212249">Prince HM, Duvic M, Martin A, et al.: Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28 (11): 1870-7, 2010.</Citation><Citation idx="17" PMID="8522487" MedlineID="96087569">Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 9 (5): 1109-16, 1995.</Citation><Citation idx="18" PMID="2808792" MedlineID="90037735">Zackheim HS, Epstein EH Jr: Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 21 (4 Pt 1): 757-62, 1989.</Citation><Citation idx="19" PMID="3543674" MedlineID="87115645">Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316 (6): 297-303, 1987.</Citation><Citation idx="20" PMID="2191335" MedlineID="90280574">Heald PW, Perez MI, McKiernan G, et al.: Extracorporeal photochemotherapy for CTCL. Prog Clin Biol Res 337: 443-7, 1990.</Citation><Citation idx="21" PMID="18241274">Scarisbrick JJ, Taylor P, Holtick U, et al.: U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 158 (4): 659-78, 2008.</Citation><Citation idx="22" PMID="23069814">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013.</Citation><Citation idx="23" PMID="16172308">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005.</Citation><Citation idx="24" PMID="11331325" MedlineID="21229775">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.</Citation><Citation idx="25" PMID="14576658">Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 49 (5): 801-15, 2003.</Citation><Citation idx="26" PMID="14576667">Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003.</Citation><Citation idx="27" PMID="23045580">Dummer R, Quaglino P, Becker JC, et al.: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30 (33): 4091-7, 2012.</Citation><Citation idx="28" PMID="12942567">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003.</Citation><Citation idx="29" PMID="18559761">Quereux G, Marques S, Nguyen JM, et al.: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144 (6): 727-33, 2008.</Citation><Citation idx="30" PMID="22981498">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013.</Citation><Citation idx="31" PMID="17577020">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007.</Citation><Citation idx="32" PMID="19826128">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009.</Citation><Citation idx="33" PMID="22394596">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012.</Citation></ReferenceSection></SummarySection><SummarySection id="_87"><SectMetaData><SpecificDiagnosis ref="CDR0000038227">stage IV mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Stage IV Mycosis Fungoides and the Sézary Syndrome</Title><Para id="_88">The use of single alkylating agents has produced objective responses in 60% of
patients with a duration of less than 6 months.  One of the alkylating agents
(e.g., mechlorethamine, cyclophosphamide, or chlorambucil), or the antimetabolite
methotrexate is the most frequently used.  Single agents have not been shown to
cure any patients, and insufficient data exist to determine if these
agents prolong survival.  Combination chemotherapy is not definitely superior
to single agents.  Even in stage IV disease, treatments directed at the skin
may provide significant palliation.  
</Para><Para id="_89">A randomized study of 103 patients compared combined total-skin electron-beam radiation
(TSEB) plus combination chemotherapy with conservation therapy consisting of
sequential topical therapies.<Reference refidx="1"/>  In the latter group, combination
chemotherapy was reserved for symptomatic extracutaneous disease or for disease
refractory to topical therapies.  Patients with any stage were eligible. 
Although the complete response rate was higher with combined therapy, toxic
effects were considerably greater, and no difference was seen in disease-free
or overall survival between the  two groups.<Reference refidx="1"/>[<LOERef href="CDR0000335125">Level of evidence: 1iiA</LOERef>]

</Para><Para id="_90"><Strong>Treatment options:</Strong><Reference refidx="2"/><Reference refidx="3"/></Para><OrderedList id="_109" Style="Arabic" Compact="No"><ListItem>Psoralen and ultraviolet A radiation (PUVA).   Therapeutic trials with PUVA
have shown a 62% to 90% complete remission rate with early cutaneous stages
achieving the best responses.  PUVA may be used in conjunction with systemic
treatment.  Maintenance therapy with PUVA is generally required to prolong
remission duration.<Reference refidx="4"/>  PUVA combined with interferon alpha-2a is associated
with a high response rate.<Reference refidx="5"/>
</ListItem><ListItem>TSEB.  Electron radiation of
appropriate energies will penetrate only to the dermis, and the skin alone
can be treated without systemic effects.  This therapy requires an excellent
radiation therapy facility with physics support, considerable technical
expertise, and precise dosimetry.  This therapy can produce excellent
palliation and may be combined with systemic treatment.<Reference refidx="6"/><Reference refidx="7"/></ListItem><ListItem>Ultraviolet B radiation is under clinical evaluation.</ListItem><ListItem>Symptomatic management with topical corticosteroids.</ListItem><ListItem>Local electron-beam radiation or orthovoltage radiation therapy may also
be used to palliate areas of bulky or symptomatic disease.<Reference refidx="8"/>
</ListItem><ListItem>Fludarabine, 2-chlorodeoxyadenosine, and pentostatin are active agents for
mycosis fungoides  and Sézary syndrome.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/></ListItem><ListItem>Interferon-alpha alone or in combination with topical therapy, as evidenced in the  ECOG-1495 trial.<Reference refidx="10"/><Reference refidx="12"/>
</ListItem><ListItem>Denileukin diftitox (interleukin-2 fused with diphtheria toxin).<Reference refidx="3"/><Reference refidx="13"/><Reference refidx="14"/></ListItem><ListItem>Systemic chemotherapy: chlorambucil plus prednisone, mechlorethamine,
cyclophosphamide, methotrexate, and combination chemotherapy.<Reference refidx="1"/><Reference refidx="15"/><Reference refidx="16"/></ListItem><ListItem>Topical mechlorethamine (nitrogen mustard). This form of treatment may be
used palliatively or to supplement therapeutic approaches directed against
nodal or visceral disease.  The overall complete remission rate in 243 patients
was 64% and was related to stage; as many as 35% of stage IV patients had complete
responses.  Treatments are usually continued for 2 to 3 years.<Reference refidx="17"/><Reference refidx="18"/>
</ListItem><ListItem>Extracorporeal photochemotherapy alone <Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/> or in combination with
TSEB.<Reference refidx="23"/>
</ListItem><ListItem>Serotherapy with monoclonal antibodies.<Reference refidx="24"/><Reference refidx="25"/></ListItem><ListItem>Bexarotene, an oral or topical retinoid.<Reference refidx="26"/><Reference refidx="27"/>
</ListItem><ListItem>Oral methotrexate (<ProtocolRef href="CDR0000533393" nct_id="NCT00425555">NCT00425555</ProtocolRef>).<Reference refidx="28"/></ListItem><ListItem>Pegylated liposomal doxorubicin.<Reference refidx="29"/><Reference refidx="30"/><Reference refidx="31"/></ListItem><ListItem>Vorinostat or romidepsin or other histone deacetylase inhibitors.<Reference refidx="32"/><Reference refidx="33"/><Reference refidx="34"/></ListItem><ListItem>Pralatrexate (folate analog).<Reference refidx="35"/></ListItem><ListItem>Alemtuzumab (a humanized monoclonal antibody targeting the CD52 antigen).<Reference refidx="36"/></ListItem></OrderedList><SummarySection id="_TrialSearch_87_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_87_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38227&amp;tt=1&amp;format=2&amp;cn=1">stage IV mycosis fungoides/Sezary syndrome</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_87_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="2594037" MedlineID="90081777">Kaye FJ, Bunn PA Jr, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321 (26): 1784-90, 1989.</Citation><Citation idx="2" PMID="16574401">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.</Citation><Citation idx="3" PMID="20212249">Prince HM, Duvic M, Martin A, et al.: Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28 (11): 1870-7, 2010.</Citation><Citation idx="4" PMID="7622650" MedlineID="95348292">Herrmann JJ, Roenigk HH Jr, Hurria A, et al.: Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol 33 (2 Pt 1): 234-42, 1995.</Citation><Citation idx="5" PMID="7799028" MedlineID="95096954">Kuzel TM, Roenigk HH Jr, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.</Citation><Citation idx="6" PMID="10223240" MedlineID="99237751">Jones GW, Rosenthal D, Wilson LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Cancer 85 (9): 1985-95, 1999.</Citation><Citation idx="7" PMID="21576575">Navi D, Riaz N, Levin YS, et al.: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 147 (5): 561-7, 2011.</Citation><Citation idx="8" PMID="22818412">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013.</Citation><Citation idx="9" PMID="1353380" MedlineID="92345592">Saven A, Carrera CJ, Carson DA, et al.: 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. Blood 80 (3): 587-92, 1992.</Citation><Citation idx="10" PMID="1453206" MedlineID="93085392">Foss FM, Ihde DC, Breneman DL, et al.: Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 10 (12): 1907-13, 1992.</Citation><Citation idx="11" PMID="7931473" MedlineID="95016867">Foss FM, Ihde DC, Linnoila IR, et al.: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 12 (10): 2051-9, 1994.</Citation><Citation idx="12" PMID="8522486" MedlineID="96087568">Olsen EA, Bunn PA: Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 9 (5): 1089-107, 1995.</Citation><Citation idx="13" PMID="22738414">Prince HM, Martin AG, Olsen EA, et al.: Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. Leuk Lymphoma 54 (1): 69-75, 2013.</Citation><Citation idx="14" PMID="11208829" MedlineID="21126170">Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2): 376-88, 2001.</Citation><Citation idx="15" PMID="8522487" MedlineID="96087569">Rosen ST, Foss FM: Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin North Am 9 (5): 1109-16, 1995.</Citation><Citation idx="16" PMID="2808792" MedlineID="90037735">Zackheim HS, Epstein EH Jr: Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 21 (4 Pt 1): 757-62, 1989.</Citation><Citation idx="17" PMID="23069814">Lessin SR, Duvic M, Guitart J, et al.: Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol 149 (1): 25-32, 2013.</Citation><Citation idx="18" PMID="16172308">de Quatrebarbes J, Estève E, Bagot M, et al.: Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study. Arch Dermatol 141 (9): 1117-20, 2005.</Citation><Citation idx="19" PMID="3543674" MedlineID="87115645">Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316 (6): 297-303, 1987.</Citation><Citation idx="20" PMID="2191335" MedlineID="90280574">Heald PW, Perez MI, McKiernan G, et al.: Extracorporeal photochemotherapy for CTCL. Prog Clin Biol Res 337: 443-7, 1990.</Citation><Citation idx="21" PMID="9722731" MedlineID="98389955">Fraser-Andrews E, Seed P, Whittaker S, et al.: Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 134 (8): 1001-5, 1998.</Citation><Citation idx="22" PMID="18241274">Scarisbrick JJ, Taylor P, Holtick U, et al.: U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol 158 (4): 659-78, 2008.</Citation><Citation idx="23" PMID="2032326" MedlineID="91235394">Palareti G, Maccaferri M, Manotti C, et al.: Fibrinogen assays: a collaborative study of six different methods. C.I.S.M.E.L. Comitato Italiano per la Standardizzazione dei Metodi in Ematologia e Laboratorio. Clin Chem 37 (5): 714-9, 1991.</Citation><Citation idx="24" PMID="1984796" MedlineID="91084586">Knox SJ, Levy R, Hodgkinson S, et al.: Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 77 (1): 20-30, 1991.</Citation><Citation idx="25" PMID="3549989" MedlineID="87168565">Rosen ST, Zimmer AM, Goldman-Leikin R, et al.: Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 5 (4): 562-73, 1987.</Citation><Citation idx="26" PMID="11331325" MedlineID="21229775">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.</Citation><Citation idx="27" PMID="14576658">Heald P, Mehlmauer M, Martin AG, et al.: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol 49 (5): 801-15, 2003.</Citation><Citation idx="28" PMID="14576667">Zackheim HS, Kashani-Sabet M, McMillan A: Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol 49 (5): 873-8, 2003.</Citation><Citation idx="29" PMID="23045580">Dummer R, Quaglino P, Becker JC, et al.: Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30 (33): 4091-7, 2012.</Citation><Citation idx="30" PMID="12942567">Wollina U, Dummer R, Brockmeyer NH, et al.: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 98 (5): 993-1001, 2003.</Citation><Citation idx="31" PMID="18559761">Quereux G, Marques S, Nguyen JM, et al.: Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol 144 (6): 727-33, 2008.</Citation><Citation idx="32" PMID="22981498">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013.</Citation><Citation idx="33" PMID="17577020">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007.</Citation><Citation idx="34" PMID="19826128">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009.</Citation><Citation idx="35" PMID="22394596">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012.</Citation><Citation idx="36" PMID="21145619">Olsen EA, Rook AH, Zic J, et al.: Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am Acad Dermatol 64 (2): 352-404, 2011.</Citation></ReferenceSection></SummarySection><SummarySection id="_102"><SectMetaData><SpecificDiagnosis ref="CDR0000038228">recurrent mycosis fungoides/Sezary syndrome</SpecificDiagnosis><SectionType>Treatment options for recurrent cancer</SectionType></SectMetaData><Title>Recurrent Mycosis Fungoides and the Sézary Syndrome</Title><Para id="_103">The treatment of relapsed patients with cutaneous T-cell lymphomas involves the joint decisions of the dermatologist, medical oncologist, and
radiation oncologist.  It may be possible to re-treat localized areas of
relapse in the skin with additional electron-beam radiation or possibly to repeat total-skin electron-beam radiation therapy (TSEB).<Reference refidx="1"/>  Photon radiation to bulky skin or
nodal masses may prove beneficial.  If these options are not possible, then
continued topical treatment with other modalities such as mechlorethamine or
psoralen and ultraviolet A radiation (PUVA) may be warranted to relieve
cutaneous symptoms.  
</Para><Para id="_114">Clinical trials, if possible, should be considered as the next therapeutic
option. Options under clinical evaluation include:<Reference refidx="2"/><Reference refidx="3"/></Para><ItemizedList id="_115" Style="bullet"><ListItem>Additional electron-beam radiation or a repeat of TSEB.</ListItem><ListItem>Photon radiation to bulky skin or nodal masses.<Reference refidx="4"/></ListItem><ListItem>Topical treatment with mechlorethamine or PUVA.</ListItem><ListItem>PUVA combined with interferon alpha-2a is associated with a high
response rate.<Reference refidx="5"/></ListItem><ListItem>Ultraviolet B radiation.</ListItem><ListItem>Symptomatic management with topical corticosteroids.</ListItem><ListItem>Extracorporeal photochemotherapy has produced tumor
regression in patients resistant to other therapies.<Reference refidx="6"/><Reference refidx="7"/></ListItem><ListItem>  The interleukin-2 fusion toxin, denileukin diftitox.<Reference refidx="3"/><Reference refidx="8"/><Reference refidx="9"/></ListItem><ListItem>Bexarotene is a retinoid available in an oral or topical form.<Reference refidx="10"/><Reference refidx="11"/></ListItem><ListItem>Allogeneic or autologous bone
marrow transplantation.<Reference refidx="12"/><Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/></ListItem><ListItem>Vorinostat or romidepsin or other histone deacetylase inhibitors.<Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/></ListItem><ListItem>Pralatrexate (folate analog).<Reference refidx="19"/></ListItem></ItemizedList><SummarySection id="_TrialSearch_102_sid_9"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_102_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38228&amp;tt=1&amp;format=2&amp;cn=1">recurrent mycosis fungoides/Sezary syndrome</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_102_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="7635786" MedlineID="95362609">Becker M, Hoppe RT, Knox SJ: Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys 32 (5): 1445-9, 1995.</Citation><Citation idx="2" PMID="16574401">Trautinger F, Knobler R, Willemze R, et al.: EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 42 (8): 1014-30, 2006.</Citation><Citation idx="3" PMID="20212249">Prince HM, Duvic M, Martin A, et al.: Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 28 (11): 1870-7, 2010.</Citation><Citation idx="4" PMID="22818412">Thomas TO, Agrawal P, Guitart J, et al.: Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys 85 (3): 747-53, 2013.</Citation><Citation idx="5" PMID="7799028" MedlineID="95096954">Kuzel TM, Roenigk HH Jr, Samuelson E, et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 13 (1): 257-63, 1995.</Citation><Citation idx="6" PMID="3543674" MedlineID="87115645">Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316 (6): 297-303, 1987.</Citation><Citation idx="7" PMID="2191335" MedlineID="90280574">Heald PW, Perez MI, McKiernan G, et al.: Extracorporeal photochemotherapy for CTCL. Prog Clin Biol Res 337: 443-7, 1990.</Citation><Citation idx="8" PMID="22738414">Prince HM, Martin AG, Olsen EA, et al.: Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. Leuk Lymphoma 54 (1): 69-75, 2013.</Citation><Citation idx="9" PMID="11208829" MedlineID="21126170">Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19 (2): 376-88, 2001.</Citation><Citation idx="10" PMID="9053506" MedlineID="97178773">Miller VA, Benedetti FM, Rigas JR, et al.: Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 15 (2): 790-5, 1997.</Citation><Citation idx="11" PMID="11331325" MedlineID="21229775">Duvic M, Hymes K, Heald P, et al.: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19 (9): 2456-71, 2001.</Citation><Citation idx="12" PMID="16135483">Molina A, Zain J, Arber DA, et al.: Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23 (25): 6163-71, 2005.</Citation><Citation idx="13" PMID="20351328">Duvic M, Donato M, Dabaja B, et al.: Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 28 (14): 2365-72, 2010.</Citation><Citation idx="14" PMID="20697072">Duarte RF, Canals C, Onida F, et al.: Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28 (29): 4492-9, 2010.</Citation><Citation idx="15" PMID="22258991">Schlaak M, Pickenhain J, Theurich S, et al.: Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 1: CD008908, 2012.</Citation><Citation idx="16" PMID="22981498">Duvic M, Dummer R, Becker JC, et al.: Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial. Eur J Cancer 49 (2): 386-94, 2013.</Citation><Citation idx="17" PMID="17577020">Olsen EA, Kim YH, Kuzel TM, et al.: Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 25 (21): 3109-15, 2007.</Citation><Citation idx="18" PMID="19826128">Piekarz RL, Frye R, Turner M, et al.: Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 27 (32): 5410-7, 2009.</Citation><Citation idx="19" PMID="22394596">Horwitz SM, Kim YH, Foss F, et al.: Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 119 (18): 4115-22, 2012.</Citation></ReferenceSection></SummarySection><SummarySection id="_212"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (02/25/2015)</Title><Para id="_213">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_289"><Strong><SummaryRef href="CDR0000062881#_1" url="/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">General Information About Mycosis Fungoides and Sézary Syndrome</SummaryRef></Strong></Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062881#_AboutThis_1" url="http://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of mycosis fungoides and the Sézary Syndrome. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewer for Mycosis Fungoides and the Sézary Syndrome Treatment is:</Para><ItemizedList Style="bullet"><ListItem>Eric J. Seifter, MD (Johns Hopkins University)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Mycosis Fungoides and the Sézary Syndrome Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq">http://www.cancer.gov/types/lymphoma/hp/mycosis-fungoides-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-02-25</DateLastModified></Summary>
